No Data
Fanpep---In August, skin care cosmetics will be released in the functional peptide sales of the 3rd quarter.
Fanpep <4881> announced its consolidated financial results for the third quarter of the fiscal year ending December 2024 (January-September 24). Revenue increased by 560.8% year-on-year to 0.003 billion yen, operating loss was 0.579 billion yen (compared to a loss of 0.805 billion yen in the same period last year), ordinary loss was 0.565 billion yen (compared to a loss of 0.752 billion yen), and quarterly net loss attributable to the parent company's shareholders was 0.559 billion yen (compared to a loss of 0.746 billion yen). As for the antibody-induced peptide project, the antibody-induced peptide "FPP00".
FunPep 9-Mos Loss Y559.00M Vs Loss Y746.00M
FunPep: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (consolidated)
Asahi, Matsukiyo, Dentsu Group, Lancers (14th) (1379-4990)
※The above calendar is merely a schedule and may be subject to change due to the company's circumstances. --------------------------------------- November 14 (Thursday) <1379> Hokuto <1380> Akikawa Bokuen <142A> Jinjibu <1438> Gifu Landscape <1443> Giken HD <1446> Candiule <1447> SAAF HD <145A> El
The medical device notification for the biological cleaning device developed jointly with Funpep-Science has been completed.
Fan Pep <4881> announced on the 31st that its consolidated subsidiary, Fan Pep Health Care (FPHC), has developed a biological cleansing device using the science of fine bubble technology called 'MiraBelle Technology' and has completed the notification for manufacturing and sales as a medical device. FPHC has been developing the next generation of biological cleansing devices in collaboration with Science. Notification number: 26B2X10045000001, sales name: MiraBelle Body Washer. In the future, FPHC will continue to develop
Emerging markets stock digest: AVILEN surged significantly, with Immune Biosciences hitting the limit up.
Stalemate. On the 11th, after the close of trading, the performance for the fiscal year ending August 2024 was announced, and it has been in a stalemate even after starting to rise.
No Data
No Data